|Bid||12.35 x 4000|
|Ask||12.85 x 2900|
|Day's range||12.21 - 12.89|
|52-week range||10.10 - 22.40|
|Beta (5Y monthly)||1.39|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.00|
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.